X-Ray Photoelectron Spectroscopy Market Growth Globally in 2015 and Beyond

X-ray photoelectron spectroscopy is a quantitative system that is used for the measurement of empirical formulae, chemical states, and composition of elements within the material that are under investigation. XPS platforms are widely used to determine an array of biomaterials, ceramics, bones, medical implants, inorganic compounds, metals, biomolecules, polymers, and others. In 2014, the global XPS market was worth US$443.5 mn and is estimated to reach a value of US$749.8 mn by the end of 2023. The XPS market is projected to register a healthy 5.80% CAGR between 2015 and 2023.

Elemental Analysis Segment to Exhibit High Growth Rate between 2015 and 2023

The global XPS market can be segmented on the basis of type of analysis into contamination analysis, forensic analysis, elemental analysis, electronic density estimation, and others. Among these, in 2014, the elemental analysis segment dominated the overall market and is expected to remain in the leading position, exhibiting the highest growth rate in the coming years. The high growth of this segment can be attributed to its ability to analyze almost all the elements in the periodic table (except a few such as helium and hydrogen) and application of the analyzed elements in several areas. Elemental analysis is followed by contamination analysis, which held the second largest share in the global market owing to its technique of effective analysis of inorganic as well as organic contaminants so as to ensure effective results of the material in the investigation.

Obtain Report Details: http://www.transparencymarketresearch.com/nonalcoholic-steatohepatitis-market.html

The global XPS market can be classified on the basis of application into semiconductors and electronics, healthcare, and others. Among these, the healthcare segment is estimated to grow rapidly, exhibiting the highest growth rate in the next few years, owing to the presence of rigid mandates in the medical research field in order to test the effectiveness of the investigative drug molecule so as to ensure the quality and safety standards. Moreover, XPS also offers a detailed analysis of several biomedical implants, biomaterials, and investigation of different cellular components of microbial cells.

Improving Research Infrastructure and Technological Advancements to Drive Global XPS Market

The global XPS market can be divided on the basis of geography into North America, Latin America, Europe, the Middle East and Africa, and Asia Pacific. In recent years, North America and Europe led the overall XPS market. The U.S. and the U.K. XPS markets are projected to witness rapid growth in the next few years. The Asia Pacific XPS market is also estimated to exhibit a high growth rate in the coming years. The high growth of this region can be attributed to the developing infrastructure and introduction of favorable business rules and regulations in China and India. Moreover, continuous efforts implemented by the major players in order to expand their horizons in emerging countries will fuel the growth of the global XPS market in the near future.

Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=9194

In addition, the awareness of XPS in developed countries is high compared to developing countries, owing to the presence of well-equipped research infrastructure, presence of skilled workers, and favorable government funds so as to support research and development activities in developing countries.

The global XPS market is highly fragmented owing to the presence of a large number of regional players operating in the market. Nevertheless, the major players in the market are emphasizing on the expansion in developing countries such as Australia, India, and China. Some of the prominent players operating in the global market for X-ray photoelectron spectroscopy are Evans Analytical Group, Kratos Analytical ltd., VG Scienta, Ulvac PHI, Thermo Fisher Scientific, Inc., and Japan Electron Optics Lab.

Growing Trends in Nonalcoholic Steatohepatitis Therapeutics Market

According to a new market report published by Transparency Market Research “Nonalcoholic Steatohepatitis Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2025”, the nonalcoholic steatohepatitis (NASH) therapeutics market is anticipated to expand at a CAGR of 10.7% from 2015 to 2025 to reach US$20.27 bn by 2025.

Nonalcoholic Steatohepatitis (NASH) is a syndrome that advances in patients who are not alcoholic; it causes liver damage that is histologically indistinguishable from alcoholic hepatitis. The major feature in NASH is fat in the liver, along with inflammation and damage. Most people with NASH feel well and are not aware of their liver problem. However, NASH can be severe and can lead to cirrhosis, in which the liver is permanently damaged and no longer able to work properly. It develops most frequently in patients with at least one of the following risk factors as obesity, dyslipidemia, and glucose intolerance. Pathogenesis is not clearly understood but seems to be linked to insulin resistance. Most of the patients are asymptomatic. Laboratory outcomes include elevations in aminotransferase levels. Biopsy is essential to confirm the diagnosis. Treatment mainly focusses on elimination of causes and risk factors.

Read Full Report: http://www.transparencymarketresearch.com/nonalcoholic-steatohepatitis-market.html

The prevalence of NASH and NAFLD is increasing across the globe but it is more in developed regions such as North America. Both NASH and NAFLD are becoming more common, perhaps because of the greater number of Americans with obesity. In the past few years, the rate of obesity has almost doubled in adults and tripled in children. Obesity also adds to diabetes and high blood cholesterol, which can further complicate the health of people suffering from NASH. Diabetes and high blood cholesterol are also becoming more common among Americans.

Currently, no specific therapies exist for NASH treatment. The most important recommendations given to persons with this disease are weight reduction (if overweight), following a balanced and healthy diet, increasing physical activity, avoiding alcohol and avoiding unnecessary medications.

The NASH market is segmented based on drug type which includes potential phase III candidates such as Obeticholic acid (OCA), Aramchol, Saroglitazar and Elafibranor. Moreover, the report enlists the candidates in Phase I and Phase II clinical trials. Based on the drug type, Elafibranor is expected to account for a major share of this market and the market for Elafibranor is expected to grow at the highest CAGR. This growth is majorly due to Elafibranor which is considered to be the most advanced drug in this category.

Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7691

Major players in this market are Astazeneca Plc (U.K.), Intercept Pharmaceuticals Inc. (U.S.), Galmed Pharmaceuticals Ltd. (Israel), GENFIT SA (France), Gilead Sciences, Inc. (U.S.), Zydus Cadila (India), Immuron Ltd. (Australia), Conatus Pharmaceuticals (U.S.), and Tobira Therapeutics, Inc. (U.S.).

The Nonalcoholic Steatohepatitis (NASH) Therapeutics market has been segmented as follows:

Global Nonalcoholic Steatohepatitis (NASH) Therapeutics Market, By Drug Type

• Overview
• Potential Drug Candidates in Phase III
  • Obeticholic Acid (OCA)
  • Aramchol (arachidyl amido cholanoic acid)
  • Saroglitazar
  • Elafibranor

Contact us:

Transparency Market Research

90 State Street,

Suite 700,

Albany

NY - 12207

United States

Tel: +1-518-618-1030

USA - Canada Toll Free 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

Hand Hygiene Agents Market: Business Challenges, Emerging Technologies & Competitive Landscape

Hand hygiene means to keep one’s hands clean by washing hands (with soap and water), or disinfecting them with an antiseptic agent, using antiseptic handwash, antiseptic hand rub or surgical hand antisepsis to remove dirt, soil, and microorganism. Antiseptics has been recognized for more than 150 years as the single cost-effective and most prominent means of preventing hospital-acquired infection, as well as for reducing the spread of potential and deadly germs and hence risk of infections from the germs in the society which may lead to hospitalization. It is admissible in all expanse such as workplace, home, and schools. However, the importance of hand hygiene is very high in hospitals or other healthcare related setups.

The Centers for Disease Control and Prevention (CDC), World health organization (WHO) and other leading healthcare organizations has given the specific guidelines and indications for hand hygiene in healthcare. The CDC has estimated that hand hygiene reduces the number around 31% of people getting sick with diarrhea, 58% with weakened immune systems and 16-18% of respiratory illness like cold in the general population. Increase widespread of hand hygiene products will prevent infections and promote the patient's safety. There are different types of hand hygiene methods which include routine hand wash, antiseptic hand wash, antiseptic hand rub and surgical antisepsis. Preventing sickness by maintaining hand hygiene will reduce the antibiotics overuse and can also prevent people from getting sick with the germs which are resistant to antibiotics which can be difficult to treat.

Obtain Report Details: http://www.transparencymarketresearch.com/hand-hygiene-agents-market.html

The healthcare-acquired infections (HCAI) prevention and control need is driving the hand hygiene market. While the outbreaks of several infectious diseases like a spread of diarrheal and respiratory illness in many countries offering positive growth for the market. Government initiatives are also contributing to the growth of this market by launching various awareness campaigns and programs such as SAR Hand Hygiene Campaign and SAVE LIVES: Clean Your Hands annual global campaign by WHO, which was focused on patient safety and reducing health care-associated infection.

The Hand Hygiene Agent Market has been segmented on the basis of types of antiseptic agents used for washing hands in different expanses from household to heathcare sector and based on geographical regions. By types of antiseptic agents, the market has been divided into alcohols, chlorhexidine gluconate, iodine and iodophors, and quaternary ammonium compounds. An alcohol-based hand rub must contain at least 60% -95% alcohol for use in a healthcare settings for optimum results. The concentration of chlorhexidine in antiseptic hand wash should be at least 4%, while the maximum number of iodophor preparations in hand hygiene contain 7.5%–10% povidone-iodine. The quaternary ammonium compounds have a slow speed of action and used only in combination with alcohols. Due to the efficiency and the ease of using the alcohol-based hand rubs it is expected to become most popular. The alcohol based antiseptics contributing for the major share in this market, followed by Chlorhexidine and iodine based antiseptics. The rate of healthcare-associated infections was lowered when adherence to recommended hand hygiene practices were improved and antiseptic hand washing was implemented.

Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14099

On the basis of geographies, the market has been segmented into North America, Europe, Asia-pacific, Latin America, and Middle East & Africa. Because of the high awareness towards hygiene, standard guideline, and proper training to the healthcare professional and general public, North America contributes for the highest share in this market. The Adoption of hand hygiene compliance monitoring (HHCM) devices in hospitals place Europe at the second position. Followed by Asia- Pacific and Rest of the world.

The key players operating in the hand hygiene agents market are EcoHydra Technologies Ltd, GOJO Industries, Inc., Kutol Products Company, Inc., Deb Group, 3M Co., STERIS Corporation, Win-Medicare etc., are among other significant players worldwide. On the other hand, Kimberly-Clark Meritech are major companies in hygiene monitoring systems.

The report offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analyzing the present scenario and future projections based on optimistic and likely scenarios. Each research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology developments, types, applications, and the competitive landscape.

Neurological Disorder Drugs Market: Increasing Research and Development Fuels Market Growth

Europe Neurological Disorders Drugs Market: Snapshot

Neurological drugs are developed to treat neurological disorders such as epilepsy, Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, schizophrenia, traumatic brain injury, spinal cord injury, cerebrovascular diseases, and others. The growing prevalence of these disorders across the European region is anticipated to drive the demand for neurological disorder drugs market in the coming few years. The research report projects that intensifying concerns about living an adjusted life have prompted several patients to seek help. According to the study, the Europe neurological disorder drugs market was valued is expected to reach a valuation of US$32.0 bn by the end of 2024 as compared to US$18.3 bn in 2015. During the forecast years of 2016 and 2024, the overall market is expected to surge at a CAGR of CAGR of 6.4%.

Obtain Report Details: http://www.transparencymarketresearch.com/europe-neurological-disorder-drugs-market.html

Increasing Research and Development Fuels Market Growth

The Europe neurological disorders drugs market will be fueled by the growing initiatives taken by governments of several countries to educate the masses and to develop new drugs. For instance, European Parkinson's Disease Association in Europe is offering affordable medications to patients, campaigning to raise awareness, and supporting research and development activities to drive the overall neurological disorder drugs market. The market has also seen a steady emergence of several research and development programs that are focused toward developing effective drugs that come at affordable prices. The collective rise in the spending of countries on developing neurological disorder drugs is expected to improve the market’s revenue in the coming few years.

On the basis of various disorders, the market caters to disorders such as epilepsy, Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, cerebrovascular disease and others. Out of all of these segments, the cerebrovascular disease held the dominant share in terms of revenue in 2015. The World Health Organization (WHO) states that the cerebrovascular diseases, which can manifest as a stroke, migraine and headache is the common cause of worry for several patients. About 80% of the patients suffering from cerebrovascular diseases across EU% show these symptoms. Thus, this segment is expected to exhibit a robust growth rate in the coming few years.

Germany Stands out as Highest Consumer of Neurological Disorder Drugs in Europe

Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=17567

In terms of geography, the Europe neurological disorder drugs market is segmented into Germany, France, Italy, Spain, U.K., Russia, Netherlands, Switzerland, Poland, and Rest of Europe. The research report states that Germany held a significant share in the market in 2015, closely followed by France. The regions will dominate over the forecast period due to the rising prevalence of neurological disorders and improving the awareness about the diseases due to support groups and government initiatives. Furthermore, the rising pool of geriatrics in Germany will also boost the uptake of neurological disorders drugs in the coming few years.

Presently, Germany, the U.K., France, Switzerland, Italy, and Spain are the leading countries in Europe in the neurological disorder drugs market. The study indicates that Switzerland will offer several growth opportunities to the overall market as awareness about these life-altering diseases grows.

The leading players operating in the Europe neurological disorders market are Merck & Co., Boehringer Ingelheim GmbH, Bayer AG, Astra Zeneca, F-Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Novartis AG, and GlaxoSmithKline plc. Among these, Merck & Co., GlaxoSmithKline plc and Novartis AG. The research report states that the market is consolidated due to the presence of several small players in who hold significant share in the market. Most of these companies are focusing on improving their pipelines and expanding their geographical outreach to retain their dominance.

Psoriasis Treatment Market: TNF Inhibitors Report Higher Demand

Global Psoriasis Treatment Market: Snapshot

The alarming rise in the number of psoriasis patients is having the most prominent impact on the global market for psoriasis treatment. With the increasing FDA approval for novel drugs and therapies for psoriasis treatment, the market is likely to surge remarkably over the next few years. Apart from this, the presence of a strong product pipeline and the growing awareness regarding psoriasis and its treatment among people in emerging economies are also projected to propel this market in the near future.

According to Transparency Market Research (TMR), the global market for psoriasis treatment offered an opportunity worth US$7.8 bn in 2015. Researchers estimate this market to rise at a CAGR of 5.10% between 2016 and 2024 and reach US$12.1 bn by 2024.

Obtain Report Details: http://www.transparencymarketresearch.com/psoriasis-treatment-market.html

TNF Inhibitors Report Higher Demand

TNF Inhibitors, interleukin blockers, and vitamin D analogues or combination have emerged as the key products available in the worldwide market for psoriasis treatment. Driven by superior efficiency and safety, TNF inhibitors are reporting a higher demand than other products in this market. By 2024, the segment is expected to remain on top with an estimated share of more than 47% in the overall market. However, the introduction of biosimilars may limit this demand to some extent in the years to come.

Interleukin blockers, on the flip side, is projected to present a lucrative growth opportunity to market players over the coming years due to their augmenting usage and their ability to act selectively by targeting the proteins.

Increasing Pool of Psoriasis Patients to Ensure North America’s Dominance

On the basis of geography, Latin America, North America, Europe, Middle East and Africa, and Asia Pacific are considered as the prime regional market for psoriasis treatment. North America has surfaced as the key contributor to this market and is likely to retain this position in the near future. The remarkable rise in the patient pool suffering from psoriasis is projected to boost this regional market over the coming years. The presence of well-established drugmakers is also expected to have positive influence on the North America market for psoriasis treatment in the years to come.

Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=17960

Europe, although currently having a strong position in the overall market, is likely to experience a decline in the demand psoriasis treatment, following an intense competition from biosimilars over the next few years. Latin America and Asia Pacific, on the other hand, are anticipated to witness a significant rise in their respective markets over the next few years. The increasing awareness regarding psoriasis and its treatment among people in emerging economies, such as China and India, through various government and NGO campaigns is projected to stimulate the Asia Pacific market for psoriasis treatment considerably in the near future.

Biogen, LEO Pharma A/S, AbbVie Inc., AstraZeneca, Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Novartis AG, Eli Lilly & Co., and Amgen Inc. are some of the prominent players in the global market for psoriasis treatment.

Mass Spectrometer Market is Expected to Witness Highest Growth During 2016 - 2024

Global Mass Spectrometry Market: Snapshot

Of the top drivers currently augmenting the global mass spectrometry market, the leading one is the surge in the rate of technological advancements that are creating a high scope of applications for newer equipment. This includes the inclusion of the MALDI-IMS and HRAM systems that are dedicated to reducing analysis time as well as improve analysis accuracy. The market is also being driven by the growing use of mass spectrometry equipment in the analysis of fundamental chemical processes as well as life sciences and drug discovery. The global mass spectrometry market is also being driven by the growing use of these equipment in the food and beverages industry for testing, as well as the favorable rate of mergers and acquisitions that have occurred for key players. However, the global mass spectrometry market is being stifled by the high costs of new equipment as well as the high expenses of research and development efforts it takes to introduce newer technologies into the market.

The global mass spectrometer market is shown to expand at a CAGR of 8.1% within the forecast period from 2016 to 2024. The market is likely to reach a valued of US$9.99 bn by the end of 2024. It was valued at US$4.96 bn in 2015.

Obtain Report Details: http://www.transparencymarketresearch.com/mass-spectrometer-market.html

MALDI-TOF Bags Top Spot in Mass Spectrometry Product Preference

Based on product types, MALDI-TOF equipment held the leading share of over 30% in the global mass spectrometer market for 2015. This segment is additionally expected to witness a very high growth rate till 2024, owing to the growing popularity of newer instruments by companies such as Shimadzu Corporation, Thermo Fisher Scientific, and Water Corporation. MALDI-TOF equipment are known to be exceptionally prominent and advanced mass spectrometer instruments that are commonly used for used for a diverse array of chemical analysis. Additionally, the recent launch of instruments including the Vion IMS QTOF Mass Spectrometer by Waters Corporation is seen as a major driver for the overall mass spectrometer market. The high preference for MALDI-TOF over other mass spectrometers is primarily due to the simpler method of preparing samples as well as the faster rate of analysis achieved in it. The leading revenue generator for mass spectrometer globally is MALDI-TOF, followed by ICP-MS.

On the basis of applications, the global mass spectrometer market can be segmented into pharmaceuticals, biotechnology, industrial chemistry, food and beverages testing, and environmental testing. Environmental testing and food and beverages testing market are showing an exceptional rate of growth in the global mass spectrometry market, primarily due to the increasing implementations of stricter regulatory measures to ensure product quality and integrity. The global share of pharmaceutical and biotechnology industry in global mass spectrometry market was estimated to be around 55% in 2015.

Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=18917

APAC Shows High Promise of New Equipment Adoption

Geographically, the global mass spectrometer market has been segmented into North America, Europe, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America accounted for top share of the global market in 2015, on the basis of revenue, followed closely by Europe. At the same time, Asia Pacific is showing the leading rate of growth in the global mass spectrometry market, owing to a growing demand for better quality analysis tools. Latin America is expected to emerge as a highly beneficial region for players from the global mass spectrometry market due to the growing scope of applications found in mining, pharmaceuticals, and biotechnology.

In 2015, the leaders of the global mass spectrometry market included Thermo Fisher Scientific, Waters Corporation, Bruker, PerkinElmer, AB SCIEX, Charles River Laboratories, Shimadzu Corporation, and Agilent Technologies.

Autologous Matrix-induced Chondrogenesis Market: Business Challenges, Emerging Technologies & Competitive Landscape

Global Autologous Matrix-Induced Chondrogenesis Market: Snapshot

Autologous matrix-induced chondrogenesis (AMIC) applies bi-layer collagen membrane through microfracture surgery to fix the damage to the articular cartilage damage. The AMIC procedure is a one-step that uses the microfracturing method, which is an established first-line treatment. The growing demand for minimal invasive procedures and a high prevalence of bone and joint disorders are expected to drive the growth of this market across the globe. According to the research report, the global autologous matrix-induced chondrogenesis market was valued at US$89.71 mn in 2015 and is expected to be worth US$186.38 mn by 2024. Between the years of 2016 and 2024, the global market is expected to progress at a CAGR of 8.6%.

Obtain Report Details: http://www.transparencymarketresearch.com/autologous-matrix-induced-chondrogenesis-market.html

Collagen to Lead the Pack as its Usage Gains Value in Tissue Engineering Sector

On the basis of material the global autologous matrix-induced chondrogenesis market segmented into hyaluronic acid, collagen, polyethylene glycol (PEG), poly lactic-co-glycolic acid (PGLA) and others. Of these, the collagen segment held the largest share of this market in 2015, which was closely followed by hyaluronic acid. Collagen accounts for approximately 30% of all protein within the human body. Therefore, it is widely used for tissue engineering applications. High tensile strength and excellent handling properties of collagen are expected to drive the segment’s growth in the coming years.

Several players operating in the global market are focusing on developing technologically advanced products, which will ensure swift uptake of autologous matrix-induced chondrogenesis. For instance, In North America-based Geistlich Pharma, Inc. launched its line of bone harvesting instruments in February 2016. The line include products such as Geistlich SmartScraper, Geistlich SafeScraper TWIST, and Geistlich Micross.

North America to Dominate Global Market with Massive Pool of Geriatrics

In terms of geography, the autologous matrix-induced chondrogenesis market is fragmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America accounted for the largest share of the autologous matrix-induced chondrogenesis market in 2015, followed by Europe. Increasing prevalence of various bone and joint disorders such as arthritis and rheumatoid arthritis amongst the geriatric population is likely to support the growth of autologous matrix-induced chondrogenesis market in North America.

Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=19289

Autologous matrix-induced chondrogenesis market in Europe, Germany, and France accounted more than 45% share of the total Europe autologous matrix-induced chondrogenesis market in 2015. Asia Pacific is also expected to be the fastest-growing market, expanding at a phenomenal CAGR compared to other regions. Increasing demand for minimal invasive procedures and increasing disposable income, along with increasing prevalence of cancer is expected to boost the autologous matrix-induced chondrogenesis market in the region during the forecast period.

The leading players operating in the global AMIC market are JRI Orthopaedics Ltd., BioTissue AG, Anika Therapeutics, Inc., B. Braun Melsungen AG, Arthro-Kinetics, Geistlich Pharma AG, CartiHeal, Matricel GmbH, Smith & Nephew plc and Zimmer Biomet Holdings. The competitive landscape of the global market is fairly consolidated as just a few players hold a significant share in the overall market. In the coming years, these players are expected to focus on expanding their reach by penetrating into developing countries of Brazil, India, South America, and Mexico. The report indicates that this move comes as the companies are trying to bring down the cost of their products by using the cheaper skilled labor in these nations and benefit from their booming medical tourism industry.